Free Trial
NASDAQ:CRDF

Cardiff Oncology Q2 2023 Earnings Report

Cardiff Oncology logo
$2.90 -0.04 (-1.36%)
As of 04/24/2025 04:00 PM Eastern

Cardiff Oncology EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Cardiff Oncology Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.08 million
Beat/Miss
Beat by +$30.00 thousand
YoY Revenue Growth
N/A

Cardiff Oncology Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Cardiff Oncology's Q1 2025 earnings is scheduled for Thursday, May 1, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cardiff Oncology Earnings Headlines

Cardiff Oncology completes patient enrollment in CRDF-004 trial
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Cardiff Oncology (CRDF) Receives a Buy from Piper Sandler
See More Cardiff Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email.

About Cardiff Oncology

Cardiff Oncology (NASDAQ:CRDF), a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

View Cardiff Oncology Profile

More Earnings Resources from MarketBeat